Comparing Careview Communications (OTCMKTS:CRVW) and Schrodinger (NASDAQ:SDGR)

Careview Communications (OTCMKTS:CRVW) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Institutional & Insider Ownership

79.1% of Schrodinger shares are held by institutional investors. 63.9% of Careview Communications shares are held by insiders. Comparatively, 21.0% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Careview Communications and Schrodinger, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Careview Communications	0	0	0	0	0.00
Schrodinger	0	2	4	0	2.67

Schrodinger has a consensus price target of $27.83, indicating a potential upside of 46.26%. Given Schrodinger’s stronger consensus rating and higher possible upside, analysts clearly believe Schrodinger is more favorable than Careview Communications.

Earnings & Valuation

This table compares Careview Communications and Schrodinger”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Careview Communications	$8.25 million	N/A	-$4.70 million	N/A	N/A
Schrodinger	$207.54 million	6.75	-$187.12 million	($2.48)	-7.67

Careview Communications has higher earnings, but lower revenue than Schrodinger.

Profitability

This table compares Careview Communications and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Careview Communications	-46.96%	N/A	-94.89%
Schrodinger	-76.22%	-45.70%	-24.81%

Volatility and Risk

Careview Communications has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500.

Summary

Schrodinger beats Careview Communications on 7 of the 11 factors compared between the two stocks.

About Careview Communications

CareView Communications, Inc. provides video monitoring solutions in the United States. Its products include CareView Patient Safety System, a video monitoring tool to improve the practice of nursing, create a better work environment, and make the patient's hospital stay more satisfying, which is used in hospitals, nursing homes, adult living centers, and outpatient care facilities; and CareView Connect, which provides resident monitoring products and services for the long- term care industry; an array of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance; a mobile app capable of delivering an alert to the caregiver and allows them document information around that alert; and alert management and monitoring system that provides a suite of hardware and software to facilitate a data-driven solution for alert management and monitoring. The company also offers Caregiver Platform that offers caregiver connect mobile application to provide a convenient and intuitive interface to capture critical workflows, such as acknowledging and documenting alert presses by the resident. In addition, it provides SitterView and TeleMedView that allows hospital staff to use CareView's video cameras to observe and communicate with patients remotely. CareView Communications, Inc. is based in Lewisville, Texas.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.